Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Bullboard Posts
Comment by bilosellhion Jul 23, 2004 11:05am
325 Views
Post# 7739046

RE: SEC implicated in StockGate

RE: SEC implicated in StockGate thanks for that concise post! i have a suggestion - instead of worrying about all these rules, regulations, delisting requests, etc., why doesn't BT update investors with what onc is doing now, where they stand, and what they have planned near & intermediate term? is it perhaps because a 6 patient ph II prostate trial doesn't cut much mustard with investors who prefer a little more substance to the cancer cure claims? or maybe its a 2 year old application for FDA approval to commence ph I/II glio trials in the US (and no apparent movement on nih) that investors are a bit antsy about? or is it perhaps that BT has too often told people onc has plenty of cash just before he does another pp, that has turned off some larger buyers who might just be hanging around until BT decides to give them another opportunity to acquire shares at a big fat discount to market? in the end the market is still a group of buyers & sellers coming together under the laws of supply & demand and i don't see a lot of buyers lining up to buy at these "bargain" prices, especially from all those very "knowledgeable" posters who were telling people not to sell at $10 or $11, since BT is the next Bill Gates.
Bullboard Posts